Kira Oleinikov1,2, Alain Dancour3, Julia Epshtein2,4, Ariel Benson2,4, Haggi Mazeh2,5, Ilanit Tal1,2, Shay Matalon6, Carlos A Benbassat7, Dan M Livovsky3, Eran Goldin3, David J Gross1,2, Harold Jacob2,4, Simona Grozinsky-Glasberg1,2. 1. Neuroendocrine Tumor Unit, Endocrinology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2. European Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Gastroenterology Institute, Shaare Zedek Medical Center, Jerusalem, Israel. 4. Department of Gastroenterology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 5. Department of Surgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 6. Institute of Gastroenterology, Assaf Harofeh Medical Center, Zrifin, Israel. 7. Institute of Endocrinology, Assaf Harofeh Medical Center, Zrifin, Israel.
Abstract
CONTEXT: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is rapidly emerging as feasible therapy for patients with pancreatic neuroendocrine tumors (pNETs) in selected cases, as a result of its favorable safety profile. OBJECTIVE: To assess the feasibility, safety, and efficacy of EUS-RFA in a cohort of patients with functional and nonfunctional pNETs (NF-pNETs). DESIGN: Data on pNET patients treated with EUS-RFA between March 2017 and October 2018 at two tertiary centers was retrospectively analyzed. RESULTS: The cohort included 18 adults (eight women, 10 men), aged 60.4 ± 14.4 years (mean ± SD), seven insulinoma patients, and 11 patients with NF-pNETs. Twenty-seven lesions with a mean diameter of 14.3 ± 7.3 mm (range 4.5 to 30) were treated. Technical success defined as typical postablative changes on a surveillance imaging was achieved in 26 out of 27 lesions. Clinical response with normalization of glucose levels was observed in all (seven of seven) insulinoma cases within 24 hours of treatment. Overall, there were no major complications 48 hours postprocedure. No clinically significant recurrences were observed during mean follow-up of 8.7 ± 4.6 months (range 2 to 21 months). CONCLUSIONS: EUS-guided RFA of pNETs is a minimally invasive, safe, and technically feasible procedure for selected patients.
CONTEXT: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is rapidly emerging as feasible therapy for patients with pancreatic neuroendocrine tumors (pNETs) in selected cases, as a result of its favorable safety profile. OBJECTIVE: To assess the feasibility, safety, and efficacy of EUS-RFA in a cohort of patients with functional and nonfunctional pNETs (NF-pNETs). DESIGN: Data on pNET patients treated with EUS-RFA between March 2017 and October 2018 at two tertiary centers was retrospectively analyzed. RESULTS: The cohort included 18 adults (eight women, 10 men), aged 60.4 ± 14.4 years (mean ± SD), seven insulinomapatients, and 11 patients with NF-pNETs. Twenty-seven lesions with a mean diameter of 14.3 ± 7.3 mm (range 4.5 to 30) were treated. Technical success defined as typical postablative changes on a surveillance imaging was achieved in 26 out of 27 lesions. Clinical response with normalization of glucose levels was observed in all (seven of seven) insulinoma cases within 24 hours of treatment. Overall, there were no major complications 48 hours postprocedure. No clinically significant recurrences were observed during mean follow-up of 8.7 ± 4.6 months (range 2 to 21 months). CONCLUSIONS: EUS-guided RFA of pNETs is a minimally invasive, safe, and technically feasible procedure for selected patients.
Authors: Ghassan El Sayed; Levente Frim; Jamie Franklin; Raymond McCrudden; Charles Gordon; Safa Al-Shamma; Szabolcs Kiss; Péter Hegyi; Bálint Erőss; Péter Jenő Hegyi Journal: Therap Adv Gastroenterol Date: 2021-11-18 Impact factor: 4.409
Authors: Mariana Figueiredo Ferreira; Rodrigo Garces-Duran; Pierre Eisendrath; Jacques Devière; Pierre Deprez; Laurent Monino; Jean-Luc Van Laethem; Ivan Borbath Journal: Endosc Int Open Date: 2022-10-17
Authors: Muhammad Nadeem Yousaf; Hamid Ehsan; Ahmad Muneeb; Ahsan Wahab; Muhammad K Sana; Karun Neupane; Fizah S Chaudhary Journal: Front Med (Lausanne) Date: 2021-02-11